A Study of Chemoradiation in Combination With Tislelizumab as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Condition: Esophageal Squamous Cell Carcinoma Interventions: Radiation: Intensity-modulated radiotherapy (IMRT); Drug: Tislelizumab; Drug: Cisplatin; Drug: Nab paclitaxel Sponsor: Renmin Hospital of Wuhan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Esophagus Cancer | Intensity-Modulated Radiation Therapy | Research | Skin Cancer | Squamous Cell Carcinoma | Study